Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14138229 | 0.78 | CES2 (0.34) | PKMMAPTNPC1RAB9AKDM4E | |
| SCHEMBL28489414 | 0.77 | PKM (0.34) | PKMKMT2AALDH1A1CYP1A2AHR | |
| SCHEMBL1946132 | 0.77 | CYP3A4 (0.38) | PKMKMT2AALDH1A1CYP3A4MAPK1 | |
| SCHEMBL92866 | 0.76 | CES2 (0.43) | MAPTNPC1KDM4EALDH1A1LMNA | |
| SCHEMBL12762222 | 0.73 | MAPT (0.39) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22744866 | 0.73 | CES2 (0.31) | PKMNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2619099 | 0.73 | ALDH1A1 (0.44) | ALDH1A1HTTCES2CES1 | |
| SCHEMBL22134656 | 0.73 | MEN1 (0.42) | PKMKMT2AMAPTNPC1RAB9A | |
| SCHEMBL18163319 | 0.73 | CA3 (0.50) | KMT2AMAPTNPC1RAB9AKDM4E | |
| SCHEMBL12028610 | 0.73 | HPGD (0.36) | KMT2AMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2015167300-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015014791-A1 | BENZIMIDAZOLO[2,1-B][1,3]BENZOTHIAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | PKM 1541/4885KMT2A 4228/4885MAPT 4579/4885 |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | PKM 2928/4885KMT2A 48/4885MAPT 258/4885 |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | PKM 1474/4885KMT2A 4194/4885MAPT 4581/4885 |
| US-10822311-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX5, P2RX4 | PKM 1826/4885KMT2A 3955/4885MAPT 4355/4885 |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | PKM 1474/4885KMT2A 4194/4885MAPT 4581/4885 |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | PKM 1541/4885KMT2A 4228/4885MAPT 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.